Using artificial intelligence to study kidney tumours from CT scans and tissue slides
Tests artificial intelligence on CT scans and tissue slides in adults having kidney tumour surgery.
Key facts
- Who runs it
- Shao Pengfei
- Where
- Nanjing, ChinaSee the site
- Trial code
- Registry title
- Optimising Renal Tumour Management Through Artificial Intelligence Modules
- Status
- Recruiting
- People taking part
- 2,100 people, planned
- Started
- 1 Jan 2025
- Expected to end
- 31 Dec 2033
- Type of study
- Observational
- Record updated
- 19 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a kidney tumour that can be treated by surgery. They need a contrast CT scan within 30 days before the operation.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Kidney tumour that can be treated by surgery; the tumour must not have already spread (metastasized) when it was found
- Earlier treatment
- No earlier treatment of any kind, including surgery, targeted therapy and immunotherapy
Main reasons for not taking part
- Missing any item of the baseline clinical and pathological information
- Tumour already spread (metastasized) when it was found
- Any earlier treatment, including surgery, targeted therapy or immunotherapy
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patients with renal tumor which can be treated by surgery
- Complete CECT within 30 days before surgery
- Patients who fully understand this study and sign the informed consent
Who cannot take part
- Previous treatment in any form, including surgery, targeted therapy and immunotherapy
- Patients with any item missing from the baseline clinical and pathological information
- Patients who has already metastasized by the time the tumor is discovered
Where in China
- The First Affiliated Hospital of Nanjing Medical University (Jiangsu Provincial People's Hospital)Nanjing, ChinaContact: Shao Pengfei, ProfessorTaking people
About the trial
What the trial wants to find out
The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are:
Read full original descriptionShow less
1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images. 2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor. 3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival.
Participants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Mutimodal Artificial Intelligence for Optimising Renal Tumour Management: Diagnosis, Surgery and Prognosis
- Plain-language title
- Using artificial intelligence to study kidney tumours from CT scans and tissue slidesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 March 2025